文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

联合应用多重PCR与血清降钙素原减少社区获得性肺炎危重症患者抗生素暴露:MULTI-CAP随机对照试验

Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial.
PubMed 文献 · Intensive Care Med · 2025-07-15
一句话结论在ICU社区获得性肺炎患者中,联合mPCR与降钙素原的管理策略未能减少第28天无抗生素存活天数或改善结局。

MULTI-CAP为多中心(n=20)、平行组、优效性、开放标签随机对照试验,纳入非免疫抑制成人(≥18岁)因社区获得性肺炎入住ICU者,1:1随机。干预组联合广谱呼吸道mPCR与常规微生物检查,并依据mPCR结果和血清降钙素原执行早期停用或降阶梯抗生素算法;对照组仅行常规微生物检查。两组均从第3天起每日根据降钙素原值及动力学考虑停用抗生素直至第7天。主要终点为入组至第28天无任何抗生素存活天数,干预组19.0(0.0; 24.0)天 vs 对照组19.0(7.0; 22.0)天,差值0.0(95%CI -4.0至4.0);第28天抗生素累积疗程干预组缩短3天(95%CI -5.1至-0.9);严重不良事件两组无差异。

要点

  • ICU社区获得性肺炎患者中,mPCR联合降钙素原策略未减少第28天无抗生素存活天数:干预组19.0(0.0; 24.0)天 vs 对照组19.0(7.0; 22.0)天,差值0.0(95%CI -4.0至4.0)。
  • 第28天抗生素累积疗程干预组较对照组缩短3天(95%CI -5.1至-0.9)。
  • 严重不良事件两组无差异。
  • 两组均从第3天起每日根据降钙素原值及动力学考虑停用抗生素直至第7天。
  • 共随机406例,意向性治疗分析可评估385例。

适用人群与场景

  • 非免疫抑制成人(≥18岁)因社区获得性肺炎入住ICU者。

处置流程与药物剂量

  • 干预组:微生物诊断联合广谱呼吸道mPCR与常规微生物检查,并依据mPCR结果和血清降钙素原执行早期停用或降阶梯抗生素算法。
  • 对照组:仅行常规微生物检查。
  • 两组均从第3天起每日根据降钙素原值及动力学考虑停用抗生素,直至第7天。

研究设计与关键结果

  • 研究类型:多中心(n=20)、平行组、优效性、开放标签随机对照试验;2018年10月4日至2022年3月3日随机406例,意向性治疗分析可评估385例。
  • 主要终点第28天无任何抗生素存活天数:干预组19.0(0.0; 24.0)天 vs 对照组19.0(7.0; 22.0)天,差值0.0(95%CI -4.0至4.0)。
  • 第28天抗生素累积疗程干预组较对照组缩短3天(95%CI -5.1至-0.9)。
  • 严重不良事件两组无差异。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(RCT)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 在ICU社区获得性肺炎患者中,联合mPCR与降钙素原的管理策略未能减少抗生素暴露或改善第28天结局,与常规诊疗相比。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Multiplex polymerase chain reaction (mPCR) testing has the potential to rapidly and accurately identify causative microorganisms in patients with community-acquired pneumonia (CAP). Its use in a management strategy, along with biomarkers, may reduce antibiotic exposure and improve clinical outcomes.

METHODS: The MULTI-CAP trial was a multicenter (n = 20), parallel-group, superiority, open-label, randomized trial. Subjects were non-immunocompromised adult patients (≥ 18 years) admitted to the intensive care unit (ICU) for CAP and randomly assigned in a 1:1 ratio. In the intervention group, the microbiological diagnosis combined a broad-spectrum respiratory mPCR and conventional microbiological investigations. An algorithm for early discontinuation or de-escalation of antibiotics was applied, based on mPCR results and serum procalcitonin. In the control group, only conventional microbiological investigations were performed. In both groups, antibiotic discontinuation was considered on Day 3 and day after day until Day 7, based on procalcitonin values and kinetics. The primary endpoint was defined as the number of days alive without any antibiotic from the time of enrollment to Day 28.

RESULTS: From October 4, 2018, to March 3, 2022, 406 patients were randomized, and 385 were evaluable in the intention-to-treat analysis. The median number of days alive without antibiotics on Day 28 was 19.0 (0.0; 24.0) days in the intervention group and 19.0 (7.0; 22.0) days in the control group (difference, 0.0 (95% CI, - 4.0 to 4.0). However, the antibiotic cumulative duration on day 28 was 3 days shorter (95% CI, - 5.1 to - 0.9) in the intervention group. Serious adverse events did not differ between groups.

CONCLUSION: In ICU patients with CAP, a management strategy combining a mPCR and serum procalcitonin failed to reduce antibiotic exposure or improve outcomes on Day 28, compared to usual care.

TRIAL REGISTRATION NUMBER: NCT03452826 (March 2018), EudraCT 2017-A01615-48.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Voiriot G, Argaud L, Cohen Y, et al. Combined use of a multiplex PCR and serum procalcitonin to reduce antibiotic exposure in critically ill patients with community-acquired pneumonia: the MULTI-CAP randomized controlled trial. Intensive Care Med. 2025. PMID: 40663137. doi:10.1007/s00134-025-08014-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。